Sol-Gel to Present at Virtual BMO 2020 Prescriptions for Success Healthcare Conference
Details are as follows: | |
Speaker: | Mr. |
Date: | |
Time: |
A live audio webcast will be available in the Investors/Events & Presentations section of the
About
Sol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages its proprietary microencapsulation technology platform for Twyneo, for the treatment of acne vulgaris, and Epsolay, for the treatment of papulopustular rosacea. The Company’s pipeline also includes SGT-210, an early-stage topical epidermal growth factor receptor inhibitor, erlotinib, for the treatment of punctate palmoplantar keratoderma, and preclinical assets tapinarof and roflumilast. For additional information, please visit www.sol-gel.com.
For further information, please contact:
Sol-Gel Contact:
Chief Financial Officer
+972-8-9313433
Investor Contact:
Solebury Trout
+1 646 378 2922
[email protected]
Source:
Source: Sol-Gel Technologies Ltd.